What happened in the premarket for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock?

0
1833
AREB Stock
AREB Stock

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), shares nosedived in the premarket ‎session today as it recorded down -33.49% to reach $61.47. There is no clear answer to why ‎this stock dropped todayother than “confused investors.” ‎

Get the hottest stocks to trade every day before the market ‎opens 100% ‎free. Click here now. 

‎The only significant piece of recent news directly affecting this stockwas that ARCT had ‎received approval from the Singapore Health Sciences Authority to initiate a Phase 2 clinical ‎study of its vaccine candidate ARCT-021. In addition to favorable Phase 1/2 results, this ‎study will build on preclinical data,supporting its efficacy.‎


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Read More

Steve Hughes, M.D., Chief Development Officer of Arcturus, said in a ‎statement that upon the basis of our promising Phase 1/2 results, we have decided to ‎advance ARCT-021 into a Phase 2 study. Based on those data and more, we believe our ‎technology can provide a highly effective yet differentiated clinical profile, including a ‎single-dose regimen.‎

Our Phase 2 study will enable us to select the optimal ARCT-021 vaccination ‎regimen for Phase 3 registration studies. We hope to have interim Phase 2 data in ‎early 2021 to provide the basis for our Phase 3 study, which is expected to be ‎initiated in Q2 2021, he added.‎

LEAVE A REPLY

Please enter your comment!
Please enter your name here